Henry Schein Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Henry Schein stock.
View analyst ratings for Henry Schein or view top-rated stocks.

Wall Street analysts have given Henry Schein a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Henry Schein wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Henry Schein, Inc. (NASDAQ:HSIC) posted its earnings results on Tuesday, August, 3rd. The company reported $1.11 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.98 by $0.13. The business had revenue of $2.97 billion for the quarter, compared to analyst estimates of $2.87 billion. Henry Schein had a net margin of 4.14% and a trailing twelve-month return on equity of 12.18%. The business's quarterly revenue was up 76.2% compared to the same quarter last year.
View Henry Schein's earnings history.

Henry Schein's stock was trading at $57.68 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HSIC stock has increased by 39.3% and is now trading at $80.37.
View which stocks have been most impacted by COVID-19.

Henry Schein's stock split on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly minted shares were payable to shareholders after the market closes on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

Henry Schein declared that its Board of Directors has authorized a stock buyback plan on Thursday, May 13th 2021, which permits the company to buyback $400,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to repurchase up to 3.6% of its stock through open market purchases. Stock buyback plans are often an indication that the company's board believes its stock is undervalued.

Henry Schein issued an update on its FY21 earnings guidance on Tuesday, August, 3rd. The company provided earnings per share (EPS) guidance of $3.85 for the period, compared to the Thomson Reuters consensus estimate of $4.15.

3 Wall Street analysts have issued 1-year price targets for Henry Schein's shares. Their forecasts range from $90.00 to $95.00. On average, they anticipate Henry Schein's stock price to reach $92.00 in the next twelve months. This suggests a possible upside of 14.5% from the stock's current price.
View analysts' price targets for Henry Schein or view top-rated stocks among Wall Street analysts.

451 employees have rated Henry Schein CEO Stanley M. Bergman on Glassdoor.com. Stanley M. Bergman has an approval rating of 94% among Henry Schein's employees. This puts Stanley M. Bergman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Henry Schein include McKesson (MCK), AmerisourceBergen (ABC), Cardinal Health (CAH), Owens & Minor (OMI) and Patterson Companies (PDCO).
View all of HSIC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Henry Schein investors own include Alibaba Group (BABA), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Intel (INTC), NVIDIA (NVDA), QUALCOMM (QCOM), CVS Health (CVS), Micron Technology (MU) and AT&T (T).

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Henry Schein's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (1.34%), New York State Common Retirement Fund (0.91%), Ardevora Asset Management LLP (0.68%), Scout Investments Inc. (0.42%), Sumitomo Mitsui Trust Holdings Inc. (0.34%) and PGGM Investments (0.31%). Company insiders that own Henry Schein stock include Deborah Derby, Gerald A Benjamin, James P Breslawski, Kurt P Kuehn, Mark E Mlotek, Michael S Ettinger, Paul Brons, Stanley M Bergman, Steven Paladino and Walter Siegel.
View institutional ownership trends for Henry Schein.

HSIC stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., New York State Common Retirement Fund, Unigestion Holding SA, State of Alaska Department of Revenue, Beacon Investment Advisory Services Inc., Zurcher Kantonalbank Zurich Cantonalbank , HGK Asset Management Inc., and Duncker Streett & Co. Inc.. Company insiders that have sold Henry Schein company stock in the last year include Gerald A Benjamin, James P Breslawski, Kurt P Kuehn, Mark E Mlotek, Michael S Ettinger, Steven Paladino, and Walter Siegel.
View insider buying and selling activity for Henry Schein or view top insider-selling stocks.

HSIC stock was bought by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB, Ardevora Asset Management LLP, Lee Danner & Bass Inc., Boston Trust Walden Corp, DAVENPORT & Co LLC, Dupont Capital Management Corp, Victory Capital Management Inc., and IFM Investors Pty Ltd.
View insider buying and selling activity for Henry Schein or or view top insider-buying stocks.

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HSIC stock can currently be purchased for approximately $80.37.

Henry Schein has a market capitalization of $11.31 billion and generates $10.12 billion in revenue each year. The company earns $403.79 million in net income (profit) each year or $2.97 on an earnings per share basis.

Henry Schein employs 19,000 workers across the globe.

The following companies are subsidiares of Henry Schein: ACE Surgical Supply Co., ADS Florida, AUV Veterinary Services, Accord, Alpha Scientific, Arcade Dentaire, Arseus, Arseus Dental Solutions, Arseus Lab, Becker-Parkin Dental Supply, BioHorizons Inc., Butler Schein Animal Health, C&M Vetlink, Camlog USA Inc., DNA Anthos Impianti, Dental Cremer, Dental Trey, Elite Computer Italia, Exan Enterprises Inc., General Injectables & Vaccines Inc., HS Brand Management Inc., HS TM Holdings LLC, Handpiece Parts & Repairs Inc., Henry Schein Europe Inc., Henry Schein Latin America Pacific Rim Inc., Henry Schein Medical Systems Inc., Henry Schein Practice Solutions Inc., Jorgen Kruuse, Lincoln Dental Supply, Logiciel Julie, MEDIVET, Maddox Practice Group, Maravet, Marrodent, Medka, Minerva Dental Limited, Modern Laboratory Services, NLS Animal Health, Noviko, Ortho Organizers, Ortho Technology, Project Helium Holdings LLC, Project Spartan Holdings Corp., RxWorks, SG Healthcare Corp, Sirona Direct, SmartPak Equine LLC, Software of Excellence, Sogim Grimouille, Southern Anesthesia & Surgical, The Exan Group, Veterinary Instrumentation, Vetstreet, W. & J. Dunlop, and scil animal care.

Henry Schein was founded in 1932.

The official website for Henry Schein is www.henryschein.com.

Henry Schein is headquartered at 135 DURYEA RD, MELVILLE NY, 11747.

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at (631) 843-5500 or via email at [email protected]